Syngoi Technologies and Ribbon Bio commence strategic collaboration to advance Gene Therapies with Synthetic DNA
Collaboration builds upon Syngoi’s synthetic DNA manufacturing capabilities and Ribbon’s algorithm-driven technology to produce pristine synthetic DNA molecules
Zamudio, Spain, March 10, 2025 — Syngoi Technologies, a leader in large scale manufacturing of synthetic DNA at clinical stage, and Ribbon Bio GmbH, the DNA synthesis company, announced today that they have begun a strategic collaboration designed to advance gene therapeutics through the development and manufacture at gram scale of clinically and commercially ready synthetic DNA. This goal of the partnership is to overcome the limitations of traditional plasmid-based DNA by answering the demand for longer, higher complexity, high-purity synthetic DNA required for next-generation gene therapies.
Plasmid DNA remains the standard in gene therapy development, but its utility is challenged by impurities, such as bacterial contaminants, as well as variability in production, inadequate supply, and complex regulatory challenges. By collaborating to produce pristine molecules of synthetic DNA, Ribbon Bio and Syngoi aim to provide a solution to these challenges, with a scalable, precise, and bacterial-free alternative that enhances therapeutic efficacy and safety.
“Our collaboration with Syngoi is yet another transformative step in the field of genetic medicine,” said Jodi Barrientos, CEO of Ribbon Bio. “Syngoi’s manufacturing capabilities will enable us together to produce synthetic DNA through a streamlined process that enables our customers to improve the safety profile of their innovative gene therapies, to deliver transformative next-generation solutions for the health of people and the planet. We look forward to working together to advance our technology.”
Syngoi’s proprietary technology enables the production of synthetic DNA with unparalleled precision and consistency at clinical grade with short delivery times. The collaboration will focus on optimizing synthetic DNA technologies for therapeutic applications and accelerating clinical developments. Through this collaboration, the two companies intend to facilitate the wider adoption of synthetic DNA as a superior alternative for scientists relying on a predictable supply of high-quality DNA to enable them to create life-saving gene therapies.
“This partnership represents a synergy of specialized expertise, where Ribbon Bio’s deep understanding of gene synthesis meets Syngoi’s cutting-edge DNA synthesis clinical manufacturing capabilities,” said José Vicente Pons, CEO of Syngoi. “Together, we are introducing a new era in gene therapies, by delivering much-needed innovative solutions for the scientific community.”
For more information, please contact:
Allison Bennet
Syngoi Technologies
abennet@syngoi.com
34-96 394 65 99
For Ribbon Bio:
Mary T. Conway
Conway Communications
mtconway@conwaycommsir.com
1-617-407-8778
